Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31094541 | 1.00 | ALDH1A1 (0.58) | ALDH1A1FKBP5TSHRNAPRTTDP1 | |
| SCHEMBL12027672 | 1.00 | — | — | |
| SCHEMBL30672606 | 0.97 | ALDH1A1 (0.55) | ALDH1A1FKBP5TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL27671601 | 0.90 | ALDH1A1 (0.62) | ALDH1A1FKBP5TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL27834115 | 0.86 | ALDH1A1 (0.72) | ALDH1A1FKBP5TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL222252 | 0.86 | ALDH1A1 (0.72) | ALDH1A1FKBP5TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL27597334 | 0.86 | ALDH1A1 (0.72) | ALDH1A1FKBP5TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL338772 | 0.86 | ALDH1A1 (0.72) | ALDH1A1FKBP5TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL12003888 | 0.83 | ALDH1A1 (0.68) | ALDH1A1FKBP5TSHRNAPRTTDP1 | |
| SCHEMBL13616372 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-09 | — | — | US | claimed |
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2023224894-A9 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | ALDH1A1 3903/4885FKBP5 2461/4885TSHR 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.